Lifesci Capital Weighs in on Immix Biopharma Q2 Earnings

Immix Biopharma, Inc. (NASDAQ:IMMX) – Stock analysts at Lifesci Capital issued their Q2 2026 earnings per share (EPS) estimates for shares of Immix Biopharma in a research note issued to investors on Wednesday, June 17th. Lifesci Capital analyst P. Dolezal anticipates that the company will earn ($0.15) per share for the quarter. Lifesci Capital currently has a “Outperform” rating and a $19.00 target price on the stock. The consensus estimate for Immix Biopharma’s current full-year earnings is ($0.70) per share. Lifesci Capital also issued estimates for Immix Biopharma’s Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.65) EPS, Q1 2027 earnings at ($0.18) EPS, Q2 2027 earnings at ($0.18) EPS, Q3 2027 earnings at ($0.18) EPS, Q4 2027 earnings at ($0.17) EPS, FY2027 earnings at ($0.70) EPS, FY2028 earnings at ($0.92) EPS, FY2029 earnings at $0.27 EPS and FY2030 earnings at $2.00 EPS.

Immix Biopharma (NASDAQ:IMMX) last issued its earnings results on Thursday, May 7th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.01.

Several other brokerages have also commented on IMMX. Wall Street Zen lowered shares of Immix Biopharma from a “hold” rating to a “sell” rating in a research note on Sunday, March 15th. Morgan Stanley initiated coverage on shares of Immix Biopharma in a research report on Wednesday, March 25th. They set an “overweight” rating and a $20.00 price objective for the company. Bank of America started coverage on shares of Immix Biopharma in a report on Thursday. They issued a “buy” rating and a $27.00 target price for the company. Mizuho increased their target price on shares of Immix Biopharma from $14.00 to $15.00 and gave the company an “outperform” rating in a research report on Monday, March 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Immix Biopharma in a research note on Tuesday, April 21st. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Immix Biopharma presently has an average rating of “Moderate Buy” and a consensus target price of $20.67.

Immix Biopharma Stock Down 4.5%

IMMX stock opened at $8.72 on Friday. The business has a 50 day moving average price of $9.20 and a 200 day moving average price of $7.75. The stock has a market cap of $474.46 million, a price-to-earnings ratio of -9.48 and a beta of 0.10. Immix Biopharma has a fifty-two week low of $1.94 and a fifty-two week high of $11.61.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in IMMX. Bank of America Corp DE increased its position in Immix Biopharma by 256,968.8% during the first quarter. Bank of America Corp DE now owns 41,131 shares of the company’s stock worth $375,000 after buying an additional 41,115 shares during the period. Janus Henderson Group PLC grew its position in shares of Immix Biopharma by 22.5% during the first quarter. Janus Henderson Group PLC now owns 4,802,002 shares of the company’s stock worth $43,698,000 after acquiring an additional 880,434 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new position in shares of Immix Biopharma in the 1st quarter valued at $264,000. Sei Investments Co. increased its holdings in shares of Immix Biopharma by 100.0% in the 1st quarter. Sei Investments Co. now owns 147,140 shares of the company’s stock valued at $1,340,000 after acquiring an additional 73,570 shares during the period. Finally, LGT Fund Management Co Ltd. increased its holdings in shares of Immix Biopharma by 233.3% in the 1st quarter. LGT Fund Management Co Ltd. now owns 416,594 shares of the company’s stock valued at $3,795,000 after acquiring an additional 291,594 shares during the period. Hedge funds and other institutional investors own 11.26% of the company’s stock.

More Immix Biopharma News

Here are the key news stories impacting Immix Biopharma this week:

• Positive Sentiment: Lifesci Capital initiated coverage with an “Outperform” rating and a $19 price target, implying substantial upside from recent levels and reinforcing a bullish long-term view. Lifesci Capital coverage note
• Positive Sentiment: The same firm issued bullish long-range earnings estimates, including $0.27 EPS for FY2029 and $2.00 EPS for FY2030, suggesting a path to meaningful profitability over time. Lifesci Capital earnings estimates
• Positive Sentiment: Earlier coverage from Bank of America also started with a Buy rating and a $27 price target, adding to the positive analyst sentiment around IMMX. Bank of America coverage
• Neutral Sentiment: Near-term earnings estimates remain negative, with Lifesci Capital projecting losses through 2028, including FY2026 EPS of -$0.65 and FY2027 EPS of -$0.70, which may temper enthusiasm despite the upbeat rating. Lifesci Capital forecast details
• Neutral Sentiment: Zacks highlighted that the consensus price target implies more than 100% upside, but this is a valuation-based outlook rather than a new business update. Zacks consensus target article

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.